Recent advances in synthetic biology have led to the development of nucleic acid polymers with backbone structures distinct from those found in nature, termed xeno-nucleic acids (XNAs).
Introduction
B cell line activation, similar to both CpG 2395 and DNA 2395. While the specific receptor involved in TNA 2395-mediated signaling remains unknown, these data clearly establish that TNA 2395 is capable of inducing innate immune responses in B cell lines.
Materials and Methods
Unless otherwise noted, all chemicals were purchased from Sigma-Aldrich (St. Louis, MO). Poly I:C was purchased from Invivogen (San Diego, CA). The synthetic TLR9 ligand, CpG ODN 2395, a type C ODN, was purchased from Invivogen (San Diego, CA). DNA 2395 was purchased from Integrated DNA Technologies (Coralville, Iowa). TNA 2395 was synthesized on an Applied Biosystems 3400 DNA synthesizer using standard β-cyanoethyl phosphoramidite chemistry with chemically synthesized TNA phosphoramidites (35) . QUANTI-Blue detection reagent for use with the HEK-Blue hTLR9 SEAP reporter cell line was purchased from Invivogen (San Diego, CA). 
Cell Stimulation
For stimulation experiments, Ramos and Raji cells were plated in 1 mL serum-free medium or serum-containing medium at a density of 2 x 10 5 cells per well in 12 well plates. HEK-Blue hTLR9 cells were plated at 5 x 10 4 cells per well in 96 well plates. Following plating (Ramos and Raji) or overnight incubation to allow adherence to the plates (HEK-Blue hTLR9), cells were stimulated with the indicated ligands (untreated/vehicle only, poly I:C, CpG ODN 2395, DNA 2395, or TNA 2395) in nuclease-free water at the indicated concentrations.
RNA Isolation and Quantitation
For isolation of total cellular RNA, Ramos cells treated with or without ligands for specified TLRs were collected by centrifugation 24 hours post-stimulation and washed twice with 1X PBS, followed by RNA isolation using TRIzol reagent (Invitrogen, Carlsbad, CA) per the manufacturer's instructions. RNA was precipitated twice and washed with 70% ethanol to remove any contaminants resulting from TRIzol RNA isolation procedures. Isolated RNA was subjected to DNase treatment using Turbo DNase (Ambion, Life Technologies, Grand Island, NY) and quantified on a NanoDrop Spectrophotometer (Thermo Fisher Scientific, Waltham, MA).
Real Time Quantitative RT-PCR
Total cellular was used to synthesize cDNA using random hexamer primers with the ImProm II Reverse Transcription System (Promega, Madison, WI) per the manufacturer's instructions. The cDNA synthesis was performed using 500 ng RNA. "No RT" and "non-template" (NT) controls were included. Prior to performing Real Time (RT) Quantitative PCR, cellular and viral cDNA, including "no RT" and "NT" controls, were validated by endpoint PCR (40 cycles) using primers specific for 18S rRNA to ensure that "no RT" and "NT" controls were free of contaminating signal. RT-qPCR was performed on each set of cDNA using iTaq Universal SYBR Green (2 -ΔΔCT ) method as previously described (37) . Samples were normalized to the specified endogenous control (18S rRNA) to determine expression level relative to total cellular RNA, and these values were plotted relative to the corresponding value for the negative controls (untreated, set to 1). Samples were assayed on the ABI 7500 (Applied Biosystems, Foster City, CA) and analyzed using ABI 7500 Software Version 2.3. Experiments were repeated three times.
Flow Cytometry
Activation of Ramos and Raji B cell lines was determined by using flow cytometry to detect surface-expressed CD86 after 24 or 72 hours post-stimulation. A phycoerythrin (PE)-labeled antibody for CD86 (B7-2) and a corresponding isotype control, mouse IgG2b kappa, were purchased from eBiosciences (now Thermo Fisher Scientific, Grand Island, NY). Following stimulation of Ramos and Raji cells for 72 hours as described in "cell stimulation," cells were collected by centrifugation and resuspended in 1X PBS. Cells were incubated with αCD86-PE or isotype control for 30 minutes at 4 o C, followed by washing twice in 1X PBS. Cells were then analyzed by flow cytometry using a BD Accuri C6 Flow Cytometer (BD Biosciences, San Jose, CA).
Proliferation Assays
Proliferation of Ramos cells in response to cell stimulation was assessed by performing cell counts 24 or 72 hours post-stimulation. Cell counts were performed by collecting cells, staining with Trypan blue to exclude non-viable cells, and counting via hemacytometer. Cell counts were confirmed by counting using a BD Accuri C6 Flow Cytometer (BD Biosciences, San Jose, CA).
Secreted Alkaline Phosphatase (SEAP) Reporter Assays
HEK-Blue hTLR9 cells were seeded at a density of 5 x 10 4 cells per well in 96 well plates. Cells were stimulated in triplicate with the indicated ligands at the indicated concentrations for either
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Differential mRNA upregulation by low and high doses of TLR9 ligands in Ramos Cells.
To explore the impact of phosphorothioate, phosphodiester, and TNA backbones on the ability of sequence 2395 to induce innate immune responses, we first sought to determine the responsiveness of the Ramos cells to low and high doses of the previously characterized, commercially available TLR9 ligand, CpG 2395 (phosphorothioate backbone), and the phosphodiester form of CpG 2395, DNA 2395. Cells were also stimulated with the TLR3 ligand,
Poly I:C, which is also known to induce innate immune responses in Ramos cells (38) , as a positive control. Ramos cells were plated in serum-free medium and stimulated with either 1 μg/mL or 10 μg/mL ligand for 24 hours. Stimulated samples were then subjected to analysis by qRT-PCR to determine RNA levels of a combination of innate immune genes including IFIT-1, IFNβ, IL-8, OAS, and TNFα. These genes were chosen to represent both the interferon response initiated through interferon regulatory factor 7 (IFIT-1, IFNβ, OAS) and the proinflammatory response initiated through NFκB (IL-8 and TNFα) that can be elicited by Class C ODNs, such as CpG 2395. As shown in Figure 1A We next wanted to determine whether the 2395 sequence synthesized with a TNA backbone was able to upregulate innate immune genes in the Ramos cells. As shown in Figure 1C In addition to activation of the Ramos cells, the 2395 sequences were analyzed for their ability to activate Raji cells. Notably, Raji cells display a higher level of CD86 expression in their unstimulated state, presumably due to the chronic Epstein Barr Virus infection of the cell line (44) . Similarly to the Ramos cells, CpG 2395, DNA 2395, and TNA 2395 were all able to upregulate CD86 expression in the Raji cells above the background level after 72 hours stimulation, albeit to a lesser extent (3-fold) ( Figure 2B ).
Together, these results confirm prior studies demonstrating that CpG ODNs containing phosphorothioate and phosphodiester backbones are able to activate B cell lines. In addition, these data also show that a TNA backbone is able to robustly activate B cell lines, despite only low-level upregulation of innate immune-associated genes examined in this study as compared to CpG 2395 and DNA 2395. In conclusion, the data presented here demonstrate that similar to CpG 2395 and DNA 2395, the 2395 sequence composed entirely of TNA is able to stimulate some innate immune responses. Notably, the ability of TNAs to induce immune responses has not previously been examined. Similar to sequences composed of phosphorothioate backbones, the TNA equivalents are highly resistant to serum nucleases (13) , making them an attractive tool for the future development of nucleic acid-based therapeutics. Recent advances in TNA synthesis using engineered polymerases have allowed for the selection of TNAs that target human thrombin (14) and HIV reverse transcriptase, opening the door for selections against a variety of other protein targets. In addition, a recent study demonstrated that antisense TNA oligonucelotides are able to effectively suppress GFP expression in living cells (17) . While a potential benefit of chemically modified nucleic acids is the ability to evade the immune Experiments were performed three times. 
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